Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma.

A retrospective series of 56 people with melanoma evaluated serial tumor-informed Signatera ctDNA for recurrence and treatment response.

BMC CancerPubMed 41928167DOI 10.1186/s12885-026-15931-5